The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma (mPC): PCRT16-001.
 
David Bing Zhen
Consulting or Advisory Role - QED Therapeutics
 
Martin Whittle
No Relationships to Disclose
 
Paul S. Ritch
No Relationships to Disclose
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Elion Oncology; Genentech; Merck
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme
 
Ben George
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Cook Medical; Eisai; Exelixis; Foundation Medicine; Ipsen; Merrimack; Roche/Genentech; Taiho Pharmaceutical; TERUMO
Research Funding - Boehringer Ingelheim (Inst); Foundation Medicine (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Roche (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst)
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - FibroGen
 
Tomislav Dragovich
Research Funding - ARMO BioSciences; Berg Pharma; Bristol-Myers Squibb (Inst); Halozyme (Inst); HolyStone Therapeutics (Inst); Kyowa Hakko Kirin; Medivir; Novocure (Inst); Rgenix
 
Steven Green
No Relationships to Disclose
 
Barbara Dion
No Relationships to Disclose
 
Amy C. Stoll-D'Astice
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Celgene (I); Cerner (I); Cigna (I); Gilead Sciences (I); Lilly (I); Moderna Therapeutics; Regeneron
 
Arthur Lee
No Relationships to Disclose
 
Shelley M. Thorsen
No Relationships to Disclose
 
Adam Rosenthal
No Relationships to Disclose
 
Sunil R. Hingorani
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Bayer; BioNTech; Ipsen; Legend Biotech; Noxxon Pharma; Noxxon Pharma; Pfizer; SOBI
Research Funding - AADi (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); FibroGen; Halozyme (Inst); Ignyta (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Ipsen; Legend Biotech